title: Characterization of in vitro ADME properties of diosgenin and dioscin from Dioscorea villosa.
abstract: Dioscorea villosa (wild yam) is native to North America and has been widely used as a natural alternative for estrogen replacement therapy to improve women's health as well as to treat inflammation, muscle spasm, and asthma. Diosgenin and dioscin (glycoside form of diosgenin) are reported to be the pharmacologically active compounds. Despite the reports of significant pharmacological properties of dioscin and diosgenin in conditions related to inflammation, cancer, diabetes, and gastrointestinal ailments, no reports are available on ADME properties of these compounds. This study was carried out to determine ADME properties of diosgenin and dioscin and their effects on major drug metabolizing enzymes (CYP 3A4, 2D6, 2C9, and 1A2). The stability was determined in simulated gastric and intestinal fluids (SGF, pH 1.2 and SIF, pH 6.8), and intestinal transport was evaluated in Caco-2 model. Phase I and phase II metabolic stability was determined in human liver microsomes and S9 fractions, respectively. Quantitative analysis of dioscin and diosgenin was performed by UPLC-MS system. Dioscin degraded up to 28.3 % in SGF and 12.4 % in SIF, which could be accounted for by its conversion to diosgenin (24.2 %. in SGF and 2.4 % in SIF). The depletion of diosgenin in SGF and SIF was < 10 %. Diosgenin was stable in HLM but disappeared in S9 fraction with a half-life of 11.3 min. In contrast, dioscin was stable in both HLM and S9 fractions. Dioscin showed higher permeability across Caco-2 monolayer with no significant efflux, while diosgenin was subjected to efflux mediated by P-glycoprotein. Diosgenin and dioscin inhibited CYP3A4 with IC50 values of 17 and 33 µM, respectively, while other CYP enzymes were not affected. In conclusion, dioscin showed better intestinal permeability. Conversion of dioscin to diosgenin was observed in both gastric and intestinal fluids. No phase I metabolism was detected for both compounds. The disappearance of diosgenin in S9 fraction indicated phase II metabolism.
authors: National Center for Natural Products Research, The University of Mississippi, University, MS, USA.
authors: Vamshi K
authors: VK
authors: Manda
authors: Bharathi
authors: B
authors: Avula
authors: Zulfiqar
authors: Z
authors: Ali
authors: Yan-Hong
authors: YH
authors: Wong
authors: Troy J
authors: TJ
authors: Smillie
authors: Ikhlas A
authors: IA
authors: Khan
authors: Shabana I
authors: SI
authors: Khan
mesh_terms: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000378:metabolism; D000893:Anti-Inflammatory Agents / Q000493:pharmacokinetics; D018938:Caco-2 Cells; D051544:Cytochrome P-450 CYP3A / Q000378:metabolism; D027742:Dioscorea / Q000737:chemistry*; D004144:Diosgenin / Q000031:analogs & derivatives / Q000378:metabolism / Q000493:pharmacokinetics*; D006207:Half-Life; D006801:Humans; D020128:Inhibitory Concentration 50; D007408:Intestinal Absorption; D050217:Metabolic Detoxication, Phase II; D010276:Parasympatholytics / Q000493:pharmacokinetics; D010539:Permeability; D010936:Plant Extracts / Q000378:metabolism / Q000493:pharmacokinetics*
chemical_list: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000893:Anti-Inflammatory Agents; D010276:Parasympatholytics; D010936:Plant Extracts; C019357:dioscin; D051544:Cytochrome P-450 CYP3A; C510163:CYP3A4 protein, human; D004144:Diosgenin
references: AAPS PharmSciTech. 2011 Jun;12(2):573-8
references: 21538213
references: Naunyn Schmiedebergs Arch Pharmacol. 1973;276(2):149-56
references: 4268465
references: J Pharm Pharmacol. 2008 Mar;60(3):363-70
references: 18284817
references: J Pharm Sci. 2007 Oct;96(10):2532-46
references: 17630644
references: Acta Medica (Hradec Kralove). 2011;54(1):3-8
references: 21542416
references: J Pharmacol Exp Ther. 2001 Oct;299(1):164-70
references: 11561076
references: PLoS One. 2012;7(10):e46641
references: 23077516
references: Carbohydr Res. 2013 Apr 5;370:86-91
references: 23454141
references: Adv Drug Deliv Rev. 2001 Mar 1;46(1-3):27-43
references: 11259831
references: Int J Pharm. 2002 Oct 10;246(1-2):85-94
references: 12270611
references: Anal Biochem. 1997 May 15;248(1):188-90
references: 9177742
references: Planta Med. 2010 Jan;76(1):62-9
references: 19639535
references: Planta Med. 2008 Aug;74(10):1269-75
references: 18612942
references: Biochem Biophys Res Commun. 1991 Mar 29;175(3):880-5
references: 1673839
references: Mol Pharm. 2009 Nov-Dec;6(6):1734-55
references: 19891494
references: Pharm Res. 1998 Aug;15(8):1160-7
references: 9706044
references: Food Chem. 2013 Jan 15;136(2):794-802
references: 23122129
references: Res Commun Mol Pathol Pharmacol. 1999 Jan;103(1):45-56
references: 10440570
references: J Pharmacol Exp Ther. 2000 Oct;295(1):360-6
references: 10992002
references: Steroids. 2005 Jul;70(8):525-30
references: 15894036
references: Planta Med. 2013 Oct;79(15):1421-8
references: 23970424
references: J Clin Pharm Ther. 1998 Dec;23(6):403-16
references: 10048501
references: Drug Metab Dispos. 2008 Jan;36(1):102-23
references: 17932224
references: Planta Med. 2007 May;73(5):421-6
references: 17566144
references: J Pharm Sci. 2010 Jun;99(6):2739-49
references: 20039391
references: Biochim Biophys Acta. 2008 Jan;1778(1):33-41
references: 18021752
references: J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Mar 25;817(2):271-5
references: 15686995
references: Pak J Biol Sci. 2011 Apr 1;14(7):425-32
references: 21902054
references: Oncol Rep. 2012 Nov;28(5):1910-6
references: 22895655
references: Expert Opin Drug Metab Toxicol. 2010 Feb;6(2):189-98
references: 20073997
references: Planta Med. 2007 Apr;73(4):330-5
references: 17372866
references: Eur J Pharmacol. 2011 Mar 5;654(2):129-34
references: 21195709
references: Planta Med. 2004 Jan;70(1):90-2
references: 14765305
references: Climacteric. 2001 Jun;4(2):144-50
references: 11428178
references: Evid Based Complement Alternat Med. 2012;2012:981675
references: 22719792